New combo aims to outsmart Hard-to-Treat HER2 cancers
NCT ID NCT07137416
First seen Jan 06, 2026 · Last updated Jun 14, 2026 · Updated 27 times
Summary
This early-phase trial tests whether adding pidnarulex to the targeted therapy trastuzumab deruxtecan is safe and effective for people with advanced HER2-expressing breast cancer or other solid tumors that have spread or can't be removed. About 36 adults whose cancer has stopped responding to standard treatments will receive the drug combination. The goal is to find the best dose and see if the combo can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Washington University School of Medicine
SUSPENDEDSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.